Pharmaceuticals and Biotech

  1. 01 Mar 2024  |  North America

    Global Orphan Drug Growth Opportunities

    Reduced Exclusivity and Increased Competition will Drive Demand for More Efficient R&D and Digital Solutions

    In this study, Frost & Sullivan s Transformational Health team provides critical insights into the global orphan drug (OD) industry and highlights growth opportunities, revenue, regulatory changes, and technology trends influencing growth. Approximately 5% of rare diseases (RDs) have received US FDA approval for a drug, while up to 15% of RDs have ...

    $4,950.00